Literature DB >> 15195320

A non-parametric approach to the design and analysis of two-dimensional dose-finding trials.

Anastasia Ivanova1, Kai Wang.   

Abstract

This paper investigates the design and analysis of dose-finding trials with two agents. The set of doses for each agent is fixed in advance. The goal of the trial is to find the set of dose combinations with probability of toxicity closest to a pre-specified value. For each of the two agents we assume that the probability of toxicity of an agent is non-decreasing with dose when the dose of the other agent is fixed. Using this assumption we construct a new non-parametric design that operates on a two-dimensional grid of all possible dose combinations. A bivariate isotonic regression estimator of the maximum tolerated combinations is described. We conclude that the new design and the bivariate isotonic estimator are superior to the procedure where several independent dose-finding trials are run. Copyright 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15195320     DOI: 10.1002/sim.1796

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  11 in total

1.  Identifying a maximum tolerated contour in two-dimensional dose finding.

Authors:  Nolan A Wages
Journal:  Stat Med       Date:  2016-02-22       Impact factor: 2.373

2.  A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies.

Authors:  Akihiro Hirakawa; Nolan A Wages; Hiroyuki Sato; Shigeyuki Matsui
Journal:  Stat Med       Date:  2015-05-13       Impact factor: 2.373

Review 3.  Implementation of adaptive methods in early-phase clinical trials.

Authors:  Gina R Petroni; Nolan A Wages; Gautier Paux; Frédéric Dubois
Journal:  Stat Med       Date:  2016-02-29       Impact factor: 2.373

4.  Advances in Statistical Approaches Oncology Drug Development.

Authors:  Anastasia Ivanova; Gary L Rosner; Olga Marchenko; Tom Parke; Inna Perevozskaya; Yanping Wang
Journal:  Ther Innov Regul Sci       Date:  2014-01       Impact factor: 1.778

Review 5.  Practical designs for Phase I combination studies in oncology.

Authors:  Nolan A Wages; Anastasia Ivanova; Olga Marchenko
Journal:  J Biopharm Stat       Date:  2016       Impact factor: 1.051

6.  Comparison of Isotonic Designs for Dose-Finding.

Authors:  Anastasia Ivanova; Nancy Flournoy
Journal:  Stat Biopharm Res       Date:  2009-02-01       Impact factor: 1.452

7.  Escalation strategies for combination therapy Phase I trials.

Authors:  Michael J Sweeting; Adrian P Mander
Journal:  Pharm Stat       Date:  2012-03-12       Impact factor: 1.894

8.  Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study.

Authors:  S J Isakoff; D Wang; M Campone; A Calles; E Leip; K Turnbull; N Bardy-Bouxin; L Duvillié; E Calvo
Journal:  Br J Cancer       Date:  2014-10-07       Impact factor: 7.640

9.  Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma.

Authors:  Randeep Sangha; Andrew Davies; Nam H Dang; Michinori Ogura; David A MacDonald; Revathi Ananthakrishnan; M Luisa Paccagnella; Erik Vandendries; Joseph Boni; Yeow Tee Goh
Journal:  J Drug Assess       Date:  2017-08-16

10.  Designing Dose-Finding Phase I Clinical Trials: Top 10 Questions That Should Be Discussed With Your Statistician.

Authors:  Shing M Lee; Nolan A Wages; Karyn A Goodman; A Craig Lockhart
Journal:  JCO Precis Oncol       Date:  2021-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.